Participants’ lipid profile (e.g., total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides), blood glucose, breast cancer biomarkers (e.g., carcinoembryonic antigen and cancer antigen 15-3), and functional fitness (e.g., strength in arms and legs, endurance, balance, agility, and flexibility) were assessed at baseline and 12-month post-intervention. This evidence concerns the gene CEACAM5 and breast cancer.